A new report (.pdf) from the Open Society Foundations, titled, “Hepatitis C Treatment: Price, Profits, and Barriers to Access,” examines “the difference in price of a 48-week course of hepatitis C treatment in low- and middle-income countries, and detail[s] breakthroughs that have been made in countries like Egypt and Thailand to negotiate lower prices and increase access to this lifesaving medicine,” according to the report summary.
The WHO “estimates that as many as 185 million people, or three percent of the world’s population, are infected with the hepatitis C virus,” the summary states, adding, “Though it is curable, the vast majority of people living with hepatitis C reside in low- and middle-income countries where treatment is virtually inaccessible” (Momenghalibaf, July 2013).
Related work:
Hepatitis C Treatment: Price, Profits, and Barriers to Access
July 29, 2013
by Azadeh Momenghalibaf
I don't understand why pharmaceutical companies make drugs to treat people, and then make them too expensive to be purchased by the people who need them. For whom are they making the drugs for, only rich sick people?
ReplyDelete